Please assess the completion status of the following clinical trial:

Trial Title: Metyrapone as Additive Treatment in Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of major depressive disorder; single or recurrent according to DSM-IV criteria (296.2 or 296.3)~* A minimum baseline Hamilton score of 18 points on the Hamilton Rating Scale for Depression (HamD; 21-item version)~* Age from 18 to 75 years~* A drug free period of at least 5 days from antidepressants, antipsychotics, mood stabilizers and all other medications except for mild antihypertensive agents~* A negative urinary drug screening diagnosis~Exclusion Criteria:~* A current DSM-IV diagnosis for other axis I psychiatric disorders~* Serious medical conditions, especially those associated with adrenal insufficiency~* Pregnancy, nursing or refusal to use a reliable method of birth control in women.~Participants were randomly assigned to a study group if they met these criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).